CR9493A - Heteroarilamidas (3.1.0)biciclicas como inhibidores del transporte de glicina de tipo i - Google Patents
Heteroarilamidas (3.1.0)biciclicas como inhibidores del transporte de glicina de tipo iInfo
- Publication number
- CR9493A CR9493A CR9493A CR9493A CR9493A CR 9493 A CR9493 A CR 9493A CR 9493 A CR9493 A CR 9493A CR 9493 A CR9493 A CR 9493A CR 9493 A CR9493 A CR 9493A
- Authority
- CR
- Costa Rica
- Prior art keywords
- heteroarilamidas
- bicycles
- inhibitors
- type
- glycine
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La presente invencion se refiere a heteroarilamidas[3.1.0]biciclicas y a composiciones farmaceuticas que las contienen, y a su uso en el tratamiento de trastornos del sistema nervioso central, trastornos cognitivos, esquizofrenia, demencia y otros trastornos en mamiferos, incluyendo seres humanos.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US66947205P | 2005-04-08 | 2005-04-08 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CR9493A true CR9493A (es) | 2007-12-04 |
Family
ID=36649611
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CR9493A CR9493A (es) | 2005-04-08 | 2007-11-01 | Heteroarilamidas (3.1.0)biciclicas como inhibidores del transporte de glicina de tipo i |
Country Status (31)
| Country | Link |
|---|---|
| US (2) | US20060229455A1 (es) |
| EP (1) | EP1869019B1 (es) |
| JP (1) | JP4193949B2 (es) |
| KR (1) | KR100969402B1 (es) |
| CN (1) | CN101189228A (es) |
| AP (1) | AP2007004198A0 (es) |
| AR (1) | AR056307A1 (es) |
| AU (1) | AU2006231917B2 (es) |
| BR (1) | BRPI0608148A2 (es) |
| CA (1) | CA2603939C (es) |
| CR (1) | CR9493A (es) |
| DK (1) | DK1869019T3 (es) |
| DO (1) | DOP2006000078A (es) |
| EA (1) | EA014311B1 (es) |
| ES (1) | ES2520015T3 (es) |
| GE (1) | GEP20105053B (es) |
| GT (1) | GT200600136A (es) |
| HN (1) | HN2006013804A (es) |
| IL (1) | IL186409A (es) |
| MA (1) | MA29672B1 (es) |
| MX (1) | MX2007012463A (es) |
| NL (1) | NL1031539C2 (es) |
| NO (1) | NO339422B1 (es) |
| NZ (1) | NZ563238A (es) |
| PE (1) | PE20061400A1 (es) |
| TN (1) | TNSN07380A1 (es) |
| TW (1) | TW200719890A (es) |
| UA (1) | UA88518C2 (es) |
| UY (1) | UY29456A1 (es) |
| WO (1) | WO2006106425A1 (es) |
| ZA (1) | ZA200708481B (es) |
Families Citing this family (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008065500A2 (en) * | 2006-11-30 | 2008-06-05 | Pfizer Products Inc. | Heteroaryl amides as type i glycine transport inhibitors |
| WO2009131958A2 (en) * | 2008-04-21 | 2009-10-29 | Institute For Oneworld Health | Compounds, compositions and methods comprising triazine derivatives |
| US8207205B2 (en) | 2008-04-21 | 2012-06-26 | Institute For Oneworld Health | Compounds, compositions and methods comprising oxadiazole derivatives |
| US20090270398A1 (en) * | 2008-04-21 | 2009-10-29 | Institute For Oneworld Health | Compounds, Compositions and Methods Comprising Pyridazine Derivatives |
| WO2010033626A1 (en) * | 2008-09-19 | 2010-03-25 | Institute For Oneworld Health | Compounds, compositions and methods comprising imidazole and triazole derivatives |
| FR2932479A1 (fr) * | 2008-06-13 | 2009-12-18 | Servier Lab | Nouveaux derives azabicycliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent. |
| ES2439291T3 (es) * | 2008-09-02 | 2014-01-22 | Janssen Pharmaceuticals, Inc. | Derivados de 3-azabiciclo[3.1.0]hexilo como moduladores de receptores de glutamato metabotrópicos |
| US8642772B2 (en) * | 2008-10-14 | 2014-02-04 | Sk Biopharmaceuticals Co., Ltd. | Piperidine compounds, pharmaceutical composition comprising the same and its use |
| WO2010107115A1 (ja) | 2009-03-19 | 2010-09-23 | 大正製薬株式会社 | グリシントランスポーター阻害物質 |
| US8343976B2 (en) | 2009-04-20 | 2013-01-01 | Institute For Oneworld Health | Compounds, compositions and methods comprising pyrazole derivatives |
| US20100267706A1 (en) * | 2009-04-20 | 2010-10-21 | Institute For Oneworld Health | Compounds, Compositions and Methods Comprising Pyridazine Derivatives |
| US8232315B2 (en) | 2009-06-26 | 2012-07-31 | Sk Biopharmaceuticals Co., Ltd. | Methods for treating drug addiction and improving addiction-related behavior |
| AR077472A1 (es) * | 2009-07-15 | 2011-08-31 | Taisho Pharmaceutical Co Ltd | Inhibidores de transportador de glicina |
| EP2496228B1 (en) | 2009-11-06 | 2014-01-15 | SK Biopharmaceuticals Co., Ltd. | Methods for treating attention-deficit/hyperactivity disorder |
| KR101783633B1 (ko) | 2009-11-06 | 2017-10-10 | 에스케이바이오팜 주식회사 | 섬유근육통 증후군의 치료 방법 |
| US8623913B2 (en) | 2010-06-30 | 2014-01-07 | Sk Biopharmaceuticals Co., Ltd. | Methods for treating restless legs syndrome |
| US9610274B2 (en) | 2010-06-30 | 2017-04-04 | Sk Biopharmaceuticals Co., Ltd. | Methods for treating bipolar disorder |
| US20120035156A1 (en) * | 2010-08-09 | 2012-02-09 | Daniela Alberati | Combination of glyt1 compound with antipsychotics |
| JP2013249257A (ja) * | 2010-09-16 | 2013-12-12 | Taisho Pharmaceutical Co Ltd | グリシントランスポーター阻害物質 |
| JP2013249258A (ja) * | 2010-09-17 | 2013-12-12 | Taisho Pharmaceutical Co Ltd | グリシントランスポーター阻害物質 |
| US8729271B2 (en) | 2010-09-17 | 2014-05-20 | Taisho Pharmaceutical Co., Ltd | Glycine transporter inhibiting substances |
| EP2621902B1 (en) | 2010-09-28 | 2017-04-12 | Panacea Biotec Ltd | 3-azabicyclo[3.1.0]hexane compounds useful for the treatment of cns disorders |
| WO2014062838A2 (en) | 2012-10-16 | 2014-04-24 | Tolero Pharmaceuticals, Inc. | Pkm2 modulators and methods for their use |
| JP6440625B2 (ja) | 2012-11-14 | 2018-12-19 | ザ・ジョンズ・ホプキンス・ユニバーシティー | 精神分裂病を処置するための方法および組成物 |
| EP3134406A1 (en) | 2014-04-24 | 2017-03-01 | Dart Neuroscience (Cayman) Ltd | Substituted 2,4,5,6-tetrahydropyrrolo[3,4-c]pyrazole and 4,5,6,7-tetrahydro-2h-pyrazolo [4,3-c]pyridine compounds as glyt1 inhibitors |
| EP3215500A1 (en) | 2014-11-05 | 2017-09-13 | Dart NeuroScience (Cayman) Ltd. | Substituted azetidinyl compounds as glyt1 inhibitors |
| MX2020005517A (es) | 2017-12-05 | 2020-11-09 | Sunovion Pharmaceuticals Inc | Formas cristalinas y metodos de produccion de las mismas. |
| US10369134B2 (en) | 2017-12-05 | 2019-08-06 | Sunovion Pharmaceuticals Inc. | Nonracemic mixtures and uses thereof |
| WO2020198077A1 (en) | 2019-03-22 | 2020-10-01 | Sumitomo Dainippon Pharma Oncology, Inc. | Compositions comprising pkm2 modulators and methods of treatment using the same |
| TW202108559A (zh) | 2019-05-31 | 2021-03-01 | 美商醫肯納腫瘤學公司 | Tead抑制劑及其用途 |
| BR112021024108A2 (pt) | 2019-05-31 | 2022-03-22 | Ikena Oncology Inc | Inibidores de tead e usos dos mesmos |
| WO2020247627A1 (en) | 2019-06-04 | 2020-12-10 | Sunovion Pharmaceuticals Inc. | Modified release formulations and uses thereof |
| KR20220125326A (ko) | 2020-01-09 | 2022-09-14 | 디스크 메디슨, 인크. | 적혈구형성 프로토포르피린증, x-연계된 프로토포르피린증, 또는 선천성 적혈구 조혈포르피린증을 글리신 운반 억제제로 치료하는 방법 |
| BR112022026698A2 (pt) | 2020-08-13 | 2023-02-23 | Boehringer Ingelheim Int | Tratamento da deficiência cognitiva associada à esquizofrenia |
| CA3195702A1 (en) | 2020-10-13 | 2022-04-21 | Boehringer Ingelheim International Gmbh | Process of reworking |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL342818A1 (en) | 1998-03-06 | 2001-07-02 | Janssen Pharmaceutica Nv | Glycin transport inhibitors |
| JP2002212179A (ja) | 2001-01-15 | 2002-07-31 | Wakunaga Pharmaceut Co Ltd | 新規アニリド誘導体又はその塩及びこれを含有する医薬 |
| EP1442018A1 (en) | 2001-10-31 | 2004-08-04 | Morphochem Aktiengesellschaft Für Kombinatorische Chemie | Novel anticancer compounds |
| FR2838739B1 (fr) | 2002-04-19 | 2004-05-28 | Sanofi Synthelabo | Derives de n-[phenyl(piperidin-2-yl)methyl)benzamide, leur preparation et leur application en therapeutique |
| US7160888B2 (en) * | 2003-08-22 | 2007-01-09 | Warner Lambert Company Llc | [1,8]naphthyridin-2-ones and related compounds for the treatment of schizophrenia |
| CN101838271A (zh) * | 2003-10-14 | 2010-09-22 | 辉瑞产品公司 | 作为甘氨酸转运蛋白抑制剂的二环[3.1.0]衍生物 |
| EP1751115A4 (en) | 2004-05-23 | 2010-10-20 | Gerard M Housey | THERAMUTEINMODULATOREN |
-
2006
- 2006-03-27 BR BRPI0608148-7A patent/BRPI0608148A2/pt not_active IP Right Cessation
- 2006-03-27 GE GEAP200610309A patent/GEP20105053B/en unknown
- 2006-03-27 JP JP2008504868A patent/JP4193949B2/ja not_active Expired - Fee Related
- 2006-03-27 EP EP06727516.4A patent/EP1869019B1/en not_active Expired - Lifetime
- 2006-03-27 AU AU2006231917A patent/AU2006231917B2/en not_active Ceased
- 2006-03-27 CA CA2603939A patent/CA2603939C/en not_active Expired - Fee Related
- 2006-03-27 WO PCT/IB2006/000947 patent/WO2006106425A1/en not_active Ceased
- 2006-03-27 CN CNA2006800198904A patent/CN101189228A/zh active Pending
- 2006-03-27 KR KR1020077025888A patent/KR100969402B1/ko not_active Expired - Fee Related
- 2006-03-27 DK DK06727516.4T patent/DK1869019T3/da active
- 2006-03-27 EA EA200701902A patent/EA014311B1/ru not_active IP Right Cessation
- 2006-03-27 NZ NZ563238A patent/NZ563238A/en not_active IP Right Cessation
- 2006-03-27 ES ES06727516.4T patent/ES2520015T3/es not_active Expired - Lifetime
- 2006-03-27 UA UAA200711021A patent/UA88518C2/ru unknown
- 2006-03-27 AP AP2007004198A patent/AP2007004198A0/xx unknown
- 2006-03-27 MX MX2007012463A patent/MX2007012463A/es active IP Right Grant
- 2006-03-31 DO DO2006000078A patent/DOP2006000078A/es unknown
- 2006-04-05 UY UY29456A patent/UY29456A1/es unknown
- 2006-04-06 PE PE2006000374A patent/PE20061400A1/es not_active Application Discontinuation
- 2006-04-06 US US11/399,071 patent/US20060229455A1/en not_active Abandoned
- 2006-04-06 AR ARP060101362A patent/AR056307A1/es unknown
- 2006-04-06 GT GT200600136A patent/GT200600136A/es unknown
- 2006-04-06 HN HN2006013804A patent/HN2006013804A/es unknown
- 2006-04-07 NL NL1031539A patent/NL1031539C2/nl not_active IP Right Cessation
- 2006-04-07 TW TW095112431A patent/TW200719890A/zh unknown
-
2007
- 2007-10-03 NO NO20074993A patent/NO339422B1/no not_active IP Right Cessation
- 2007-10-04 ZA ZA200708481A patent/ZA200708481B/xx unknown
- 2007-10-07 IL IL186409A patent/IL186409A/en active IP Right Grant
- 2007-10-08 MA MA30281A patent/MA29672B1/fr unknown
- 2007-10-08 TN TNP2007000380A patent/TNSN07380A1/fr unknown
- 2007-11-01 CR CR9493A patent/CR9493A/es not_active Application Discontinuation
-
2010
- 2010-08-30 US US12/870,928 patent/US8124639B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CR9493A (es) | Heteroarilamidas (3.1.0)biciclicas como inhibidores del transporte de glicina de tipo i | |
| CR20110095A (es) | Derivados biciclicos [3.1.0] como inhibidores del transportador de glicina (divisional solicitud 8333) | |
| ECSP066391A (es) | [1,8] naftiridin-2-onas y compuestos relacionados para el tratamiento de la esquizofrenia | |
| GT200600159A (es) | Derivados benzodioxano y benzodioxolano y usos de los mismos | |
| CR8718A (es) | Compuesto de morfolina sustituida para el tratamiento de trastornos del sistema nervioso central | |
| ECSP056019A (es) | 2,4-di(fenilamino)pirimidinas útiles en el tratamiento de enfermedades neoplásicas, trastornos inflamatorios y del sistema inmune | |
| ECSP055676A (es) | Piperazinas heterocíclicas sustituidas para el tratamiento de la esquizofrenia | |
| CL2007002910A1 (es) | Composicion farmaceutica que comprende compuestos derivados de anillos monociclicos, biciclicos o triciclicos, inhibidores de amidohidrolasa de acidos grasos; complejo que comprende al compuesto; y uso en el tratamiento de enfermedades tales como dol | |
| CL2008003593A1 (es) | Compuestos derivados de isoxazolo-piridazina; procedimiento de preparacion; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto en el tratamiento de trastornos cognitivos como el alzheimer | |
| NI200900204A (es) | COMPUESTOS AMINO-HETEROCÍCLICOS. Caso: PC 33468A | |
| ECSP077275A (es) | Novedosos derivados de heteroarilsulfamida benzofusionados utiles como agentes anticonvulsivos | |
| UY31673A1 (es) | "derivados heterocíclicos de urea y métodos de uso de los mismos-211" | |
| CL2008001560A1 (es) | Compuestos derivados de heterociclo de nitrogenado, moduladores de gamma secretasa; composicion farmaceutica que los comprende; y su uso en el tratamiento de enfermedades neurodegenerativas como el alzheimer, sindrome de down; kit farmaceutico. | |
| AR060786A1 (es) | Variaciones cristalinas de (2s)-(4e)-n-metil-5-[3-(5-isopropoxipiridin)il]-4-penten-2-amina | |
| PA8583601A1 (es) | Derivados de pirrolidona como inhibidores de maob | |
| GT200300033A (es) | Derivados de nicotinamida utiles como inhibidores de pde4 | |
| AR057239A1 (es) | Inmunoglobulinas | |
| GT200500215A (es) | Amidas sustituidas de àcido tienopirrolcarboxìlico, amidas del àcido pirrolotiazolcarboxìlico y anàlogos relacionados como inhibidores de la epsilon caseìna quinasa i | |
| PY0115427A (es) | Benzofenonas y sulfonas como inhibidores de la captacion de glicina | |
| UY27998A1 (es) | Piperazinas sustituidas sustituidas heterocíclicas para el tratamiento de la esquizofrenia | |
| SV2006002384A (es) | Pirazolo piridinas sustituidas, composiciones que las contienen, procedimiento de fabricacion y utilizacion | |
| CR7735A (es) | Piperizinas heterociclicas sustituidas para el tratamiento de la esquizofrenia | |
| CL2008003232A1 (es) | Compuestos derivados de bencensulfonanilida; composición farmacéutica que los comprende; y uso en el tratamiento de enfermedades del sistema nervioso central, disfunciones cognitivas, esquizofrenia, enfermedades adictivas, enfermedad de alzheimer u obesidad. | |
| UY29078A1 (es) | Amidas del ácido 5 y 6-aminoalquil indol-2-carboxílico 3-sustituidas y análogos relacionados como inhibidores de la caseína cinasa ie(epsilon) | |
| UY29371A1 (es) | Pirroles sustituídos, composiciones que los contienen, proceso de fabricación y utilización |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal (granting procedure) |